The recent case of the withdrawal of Albothyl drugs by PT Pharos has become a public spotlight. In addition to raising concerns among consumers, this case also raises a number of questions related to ethical business practices.Â
As a pharmaceutical company, PT Pharos has a great responsibility towards the health and safety of consumers. Therefore, it is important for us to analyze this case from a business ethics perspective.
PT Pharos, one of the leading pharmaceutical companies in Indonesia, faced criticism regarding the marketing of the Albothyl product. Albothyl is a drug known for treating infections and other conditions. The problem arose when a number of consumers claimed that the information provided about the product was inaccurate, and there were allegations that the effectiveness of the product did not match the claims marketed.
BPOM on Thursday (2/15/2018) appealed to the public to stop using Albothyl products distributed by PT Pharos Indonesia. They also instructed PT Pharos to withdraw the product from the market. Albothyl's distribution permit was temporarily suspended until BPOM approved the submitted indications.Â
Thus, the use of Albothyl as a hemostatic and antiseptic in surgery, as well as on the skin, ears, nose, throat, canker sores, and teeth is prohibited. This decision was made after BPOM received 38 reports from health workers regarding side effects from using Albothyl
Chronology of Events
1. Product Marketing:
Albothyl was marketed with claims that the drug was effective in treating infections and had various other health benefits. Marketing was carried out through various channels, including social media and advertising.
2. Consumer Complaints:
After the product was on the market, a number of consumers began to report that they did not experience any improvement after using Albothyl, and in some cases, their health conditions worsened.
3. Research and Supervision:
